Nimotuzumab is under clinical development by InnoMab and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nimotuzumab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nimotuzumab overview
Nimotuzumab (DE-766, Theraloc,TheraCIM, Laedemab, Biomab EGFR, Cimaher, Taixinsheng) is a humanized monoclonal antibody. it is formulated as solution for intravenous route of administration. Nimotuzumab is indicated for the treatment of advanced squamous cell carcinoma of head and neck and pancreatic ductal adenocarcinoma.
The drug candidate is under development for the treatment of stage III/IV head and neck squamous cell cancer, coronavirus disease 2019 (Covid-19) pneumonia, high-grade glioma, newly diagnosed diffuse intrinsic pontine glioma (DIPG), pancreatic Cancer and acute respiratory distress syndrome.
The drug candidate was under development for the treatment of metastatic esophageal cancer, squamous cell carcinoma, nasopharyngeal cancer, cervical cancer, metastatic triple negative breast cancer, glioma, gastric cancer, metastatic adenocarcinoma of pancreas, colorectal cancer, gastroesophageal junction cancer, squamous non-small cell lung carcinoma. non-small cell lung cancer and recurrent head and neck squamous cell carcinoma.
For a complete picture of Nimotuzumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
